JD Health to raise £2.99b in Hong Kong IPO - sources
written by Bella Palmer
Listings in Hong Kong so far this year have been worth £29.27 billion compared with £30.09 billion last year, according to Refinitiv data
JD Health, the healthcare arm of Chinese e-tailer JD.com Inc, aims to raise up to £2.99 billion ($4 billion) in Hong Kong's largest initial public offering (IPO) of 2020, three people with direct knowledge of the matter told Reuters.
The share sale, which starts on Wednesday, will help Hong Kong to its busiest year for IPOs and secondary listings since 2010 when issuers raised £42.95 billion ($57.39 billion), Refinitiv data showed.
Listings in Hong Kong so far this year have been worth £29.27 billion ($39.1 billion), versus £30.09 billion ($40.2 billion) last year, the data showed.
JD.com announced plans in September to spin off what, in its draft prospectus, it called mainland China's largest online healthcare platform.
Bookbuilding will open to institutional and retail investors on Wednesday, the people said, declining to be identified as the information was private.
Trading of the shares on the Hong Kong stock market is due to start in the second week of December, said a separate person with direct knowledge of the matter.
The fundraising was first reported on Monday by IFR.
JD.com raised £3.29 billion ($4.4 billion) through a secondary listing in June - Hong Kong's largest deal so far this year. The city's largest IPO of 2020 to date was that of China Bohai Bank Co Ltd at £1.50 billion ($2 billion) in July, Refinitiv data showed.
JD Health's listing reflects continued strength in Hong Kong's capital markets after Ant Group's £27.69 billion ($37 billion) Hong Kong-Shanghai IPO was pulled this month.
China Evergrande Group is spinning off its property services business to raise as much as £1.53 billion ($2.04 billion) in a Hong Kong listing, set to be priced on Thursday.
Important:
This article is for information purposes only.
Please remember that financial investments may rise or fall and past performance does not guarantee future performance in respect of income or capital growth; you may not get back the amount you invested.
There is no obligation to purchase anything but, if you decide to do so, you are strongly advised to consult a professional adviser before making any investment decisions.